Condition: ESRD, CKD Stage 4, CKD Stage 5 · Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
This is a phase II, proof of concept, placebo-controlled, randomized clinical trial, assessing the effect of canagliflozin on cardiac structure and function in patients with advanced renal disease, including those on maintenance dialysis. Our primary aim is to determine the effect of canagliflozin on cardiac structure and function in patients with advanced chronic kidney disease (CKD), compared with placebo. We hypothesize that canagliflozin will improve left ventricular (LV) hypertrophy in patients with advanced CKD. Our secondary aims are to describe the effect of canagliflozin on other cardiac magnetic resonance imaging parameters and surrogate markers of efficacy in this population.
This description comes directly from the study's public registry record.
Efrosyne Tsirella, Research Assistant · 514-934-1934 · efrosyne.tsirella@muhc.mcgill.ca
Norka Rios, Research Nurse · 514-934-1934 · norka.rios@muhc.mcgill.ca
Always discuss trial participation with your own doctor first.
| McGill University Health Center | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06182839